A recent study by Professor Andrew Hill et al i suggests that finished forms of semaglutide pens can be sold to patients for anything between $2.50-$12 per month, but this underestimates a large number of costs associated with sourcing from diverse geographies, as well as costs during the market access process
Finan B, Yang B, Ottaway N, et al
Youll get the best results that way
Data Verification Statement: All weight loss percentages, side effect rates, discontinuation data, and clinical outcomes cited in this article are derived from the sources listed above
This investigational drug is distinctive in targeting GIP, GLP-1, and glucagon receptors, a novel approach compared to existing obesity treatments
doi:10.1002/bies.10297